← Back
Pharmacology I · Exam 3 · Class of 2028

Pneumonia and Bronchitis: Empiric Regimens by Setting

Acute bronchitis, community-acquired pneumonia (outpatient, ward, intensive care) and nosocomial pneumonia (limited or broad spectrum) side by side: who belongs in each setting, the likely pathogens, the empiric regimen and what to watch. No doses.

Lecture 11 — Drugs for Pulmonary Infections, Asthma and Chronic Obstructive Pulmonary Disease 8 rows

Read the regimen column as a ladder. Outpatient pneumonia with no resistance risk gets one drug; a resistance risk adds a beta-lactam to the macrolide (or swaps both for a respiratory fluoroquinolone, the beta-lactam allergy route); the ward makes the beta-lactam intravenous; intensive care makes everything intravenous and adds thought about methicillin-resistant Staphylococcus aureus. In the hospital, the question is whether multidrug-resistant risk is present: no gives one limited-spectrum drug, yes gives three (two gram-negative drugs plus vancomycin or linezolid). Current guidelines differ on two points: they prefer amoxicillin or doxycycline over a macrolide for a healthy outpatient (macrolides only where pneumococcal resistance is low), and the 2016 hospital-acquired pneumonia guideline no longer uses health-care associated pneumonia as a category. The slides are what you are tested on. Doses are not tested and are left out.
SettingWho belongs hereLikely pathogensEmpiric regimenNotesSource
Acute bronchitisInflammation of one or more bronchi, sparing the bronchioles and alveoli; acute at any age, chronic mainly in chronic obstructive pulmonary diseaseViruses (rhinovirus, coronavirus, influenza, adenovirus); occasionally bacteria (Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis, streptococci, staphylococci, Haemophilus), sometimes after a viral illnessSupportive care; routine antibiotics not recommended. Symptoms beyond 5 days: consider bacteria — doxycycline (preferred if Mycoplasma is documented, because of macrolide resistance) or a macrolidePossibly avoid antihistamines and sympathomimetics; avoid a respiratory fluoroquinolone unless there was recent antibiotic exposureL11
slide 8
slide 5
slide 6
slide 7
Community-acquired, outpatient, no resistance riskNo risk factor for resistant S. pneumoniaeS. pneumoniae, M. pneumoniae, H. influenzae, Moraxella catarrhalis, respiratory virusesFirst line: a macrolide (azithromycin, clarithromycin). Second line: doxycycline, minocyclineEmpiric therapy; diagnostic tests not routinely performed. Current guidelines differ (see the note below).L11
slide 14
slide 12
slide 11
Community-acquired, outpatient, resistance riskAge over 65, a beta-lactam in the past 3 months, alcoholism, immunosuppression, comorbidities, a child in day care at homePenicillin-resistant S. pneumoniae on top of the outpatient listBeta-lactam plus a macrolide (amoxicillin with or without clavulanic acid; cefuroxime or cefpodoxime) or a respiratory fluoroquinolone (levofloxacin, moxifloxacin)The fluoroquinolone route suits a beta-lactam allergyL11
slide 14
slide 13
Community-acquired, inpatient (not intensive care)Admitted to the wardS. pneumoniae, M. pneumoniae, C. pneumoniae, H. influenzae, Legionella, aspiration, respiratory virusesIntravenous beta-lactam (cefotaxime, ceftriaxone, high-dose ampicillin) plus an intravenous or oral macrolide, or doxycycline, or a respiratory fluoroquinolone (beta-lactam allergy)Blood and sputum cultures before antibiotics; sputum gram stain is controversial (often contaminated)L11
slide 15
slide 12
slide 11
Community-acquired, intensive careAdmitted to the intensive care unitS. pneumoniae, Staphylococcus aureus, Legionella, gram-negative bacilli, H. influenzaeSame as the ward, all intravenousConsider MRSA (methicillin-resistant Staphylococcus aureus) coverage if warrantedL11
slide 15
slide 12
Nosocomial, limited spectrumPneumonia more than 48 hours after admission, with neither late onset (5 days or more) nor a multidrug-resistant risk factorNosocomial pathogens without multidrug resistance; levofloxacin or moxifloxacin if atypical pathogens are a worryCeftriaxone, or levofloxacin or moxifloxacin, or ampicillin/sulbactam, or ertapenemStart at once; streamline when cultures and sensitivities returnL11
slide 22
slide 21
slide 16
Nosocomial, broad spectrumLate onset (5 days or more) or a multidrug-resistant risk factor: prior antibiotics, colonization, hospitalization or chronic care, immunosuppressive disease or therapyGram-negative bacilli (Pseudomonas aeruginosa most common, E. coli, K. pneumoniae, Acinetobacter, Enterobacter, Serratia); gram-positive cocci (MRSA (methicillin-resistant Staphylococcus aureus) most common, S. pneumoniae); fungi (Candida, Aspergillus fumigatus)Antipseudomonal cephalosporin, carbapenem or penicillin/beta-lactamase inhibitor PLUS an antipseudomonal fluoroquinolone or an aminoglycoside, PLUS vancomycin or linezolidMust cover MRSA (methicillin-resistant Staphylococcus aureus) and Pseudomonas; do not wait for a definitive cultureL11
slide 23
slide 21
slide 19
slide 20
Nosocomial, after culturesCultures and sensitivities are backThe organism grownScale back coverage; switch to oral therapy when possible (cheaper)If it fails: wrong therapy, wrong diagnosis (pulmonary embolus, neoplasm) or a complication (C. difficile colitis, empyema, lung abscess)L11
slide 31